文献速递认知障碍与痴呆

达法吡啶改善多发性硬化信息处理速度损害

Effect of dalfampridine on information processing speed impairment in multiple sclerosis.
PubMed 文献 · Neurology · 2019-07-22

这项随机双盲安慰剂对照试验纳入SDMT低于参考值第10百分位的多发性硬化患者,按2:1随机接受达法吡啶10mg或安慰剂每日两次治疗12周。结果显示达法吡啶组SDMT改善优于安慰剂,但4周随访时未持续,且听觉系列加法测验和认知疲劳也有获益。

要点

  • 达法吡啶10mg每日两次可改善多发性硬化患者的信息处理速度。
  • SDMT原始分平均变化达法吡啶组9.9 vs 安慰剂组5.2,p=0.0018。
  • 疗效在停药4周随访时未持续,需关注长期效果。

核心结论

  • 达法吡啶可考虑作为多发性硬化信息处理速度损害的有效治疗选择。
  • 该研究提供I级证据表明对SDMT低分的多发性硬化患者达法吡啶改善信息处理速度。

研究设计与样本

  • 随机双盲安慰剂对照试验,纳入SDMT低于参考值第10百分位的多发性硬化患者。
  • 筛查208例,随机120例至达法吡啶组80例或安慰剂组40例,按2:1比例。
  • 达法吡啶10mg或安慰剂每日两次,治疗12周,并在筛查、治疗结束和4周随访时进行综合神经心理评估。
  • 主要终点为SDMT改善。

主要发现

  • 治疗结束时达法吡啶组SDMT原始分平均变化9.9(95%CI 8.5-11.4),安慰剂组5.2(95%CI 2.8-7.6),p=0.0018,d=0.60。
  • 治疗结束时达法吡啶组SDMT z分平均变化0.8(95%CI 0.6-1),安慰剂组0.3(95%CI 0.0-0.5),p=0.0013,d=0.61。
  • 改善在4周随访时未持续。
  • 在听觉系列加法测验和认知疲劳方面观察到达法吡啶的获益。

临床怎么用

  • 对于SDMT低于参考值第10百分位的多发性硬化患者,可考虑使用达法吡啶10mg每日两次改善信息处理速度。
  • 需注意疗效在停药4周后未持续,应评估长期治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test a possible benefit of dalfampridine on information processing speed (IPS), a key function for cognitive impairment (CogIm) in multiple sclerosis (MS). METHODS: In this randomized, double-blind, placebo-controlled trial, we included patients with a score on the Symbol Digit Modalities Test (SDMT) under the 10th percentile of the reference value. Patients were randomized in a 2:1 ratio to receive dalfampridine 10 mg or placebo twice daily for 12 weeks. They underwent a comprehensive neuropsychological evaluation at screening (T0), at the end of treatment (T1), and after a 4-week follow-up (T2). The primary endpoint was improvement in SDMT. RESULTS: Out of 208 patients screened, 120 were randomized to receive either dalfampridine (n = 80) or placebo (n = 40). At T1, the dalfampridine group presented an increase of SDMT scores vs placebo group (mean change 9.9 [95% confidence interval (CI) 8.5-11.4] vs 5.2 [95% CI 2.8-7.6], p = 0.0018; d = 0.60 for raw score; and 0.8 [95% CI 0.6-1] vs 0.3 [95% CI 0.0-0.5], p = 0.0013; d = 0.61 for z scores; by linear mixed model with robust standard error). The improvement was not sustained at T2. A beneficial effect of dalfampridine was observed in the Paced Auditory Serial Addition Test and in cognitive fatigue. CONCLUSION: Dalfampridine could be considered as an effective treatment option for IPS impairment in MS. TRIAL REGISTRATION: 2013-002558-64 EU Clinical Trials Register. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with MS with low scores on the SDMT, dalfampridine improves IPS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. De Giglio L, De Luca F, Gurreri F, et al. Effect of dalfampridine on information processing speed impairment in multiple sclerosis. Neurology. 2019. PMID: 31331968. doi:10.1212/WNL.0000000000007970

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。